New study tests oral antiviral for newborns exposed to herpes
NCT ID NCT05468619
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 study tested different doses of the oral antiviral drug valacyclovir in 17 newborns whose mothers had genital herpes. The goal was to find a dose that gives similar drug levels in the blood as the standard IV treatment. Researchers measured how the drug was processed and checked for side effects. The study is complete and helps guide future dosing for infants at risk of neonatal herpes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Valacyclovir (an antiviral drug given by mouth)
What this could lead to
If successful, this could help doctors give oral valacyclovir to newborns at risk of herpes, avoiding the need for IV treatment.
What could go wrong
This is a very early, small Phase 1 study with only 17 infants. It focuses on dosing and safety, not on curing or preventing disease. Results may not apply to all newborns.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES SIMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health ID Consultants & Infusion Care Specialists
Charlotte, North Carolina, 28207, United States
-
Children's Nebraska
Omaha, Nebraska, 68114-4108, United States
-
Children's of Alabama Child Health Research Unit (CHRU)
Birmingham, Alabama, 35233-0011, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30322-1014, United States
-
M Health Fairview Masonic Children's Hospital
Minneapolis, Minnesota, 55454, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226-3522, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205-2664, United States
-
SUNY Upstate Medical University Hospital - Pediatrics
Syracuse, New York, 13210-2342, United States
-
Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious Disease
Queens, New York, 11040, United States
-
University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases
Louisville, Kentucky, 40202, United States
-
University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases
Rochester, New York, 14642-0001, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110-1010, United States